Treatment Timelines Related to Disease State and Use of Monotherapy

Author(s):

Panelists discuss the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC), exploring main therapeutic approaches, the role of androgen deprivation monotherapy, the timing for adding chemotherapy and ARPIs, and strategies for sequencing or combining these modalities in clinical practice.

EP: 1.Treatment Landscape and Sequencing of Therapies

Now Viewing

EP: 2.Treatment Timelines Related to Disease State and Use of Monotherapy

EP: 3.Genetic Testing – Germline

EP: 4.Recent Data on ARPI-Based Combination Regimens

EP: 5.Genetic Testing – Somatic

EP: 6.ARPI-Based Combination Regimens – PEACE-3 (Radium-223 and enzalutamide)

EP: 7.Use of Bone Protection Agents

EP: 8.ARPI-Based Combination Regimens – ARANOTE (Darolutamide and ADT)

EP: 9.ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

EP: 10.ARPI-Based Combination Regimens – SPLASH (177 Lu-PNT-2002)

EP: 11.Key Takeaways and Looking Ahead

What is the current treatment landscape for metastatic castration-sensitive prostate cancer (mHSPC)? What are the main therapeutic approaches typically utilized for these patients?
Is there still a role for androgen deprivation monotherapy in any setting? Why or why not?
When do you consider the addition of chemotherapy and ARPIs?
How do you approach sequencing or combining these different modalities in your practice?